- 2024-08-20 01:55抑制剂FT-1518|FT-1518|1313026-58-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:55抑制剂FOY 251|FOY 251|71079-09-9|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:55抑制剂FOY 251|FOY 251|71079-09-9|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:55抑制剂FOY 251|FOY 251|71079-09-9|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:55抑制剂Fostemsavir Tris|Fostemsavir Tris|864953-39-9|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:55抑制剂Fostemsavir Tris|Fostemsavir Tris|864953-39-9|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:55抑制剂Fostemsavir Tris|Fostemsavir Tris|864953-39-9|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:55抑制剂Fosciclopirox |Fosciclopirox |1380539-06-9|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:55抑制剂Fosciclopirox |Fosciclopirox |1380539-06-9|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:55抑制剂Fosciclopirox |Fosciclopirox |1380539-06-9|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:55抑制剂Fmoc-Thr[GalNAc(Ac)3-α-D]-OH|Fmoc-Thr[GalNAc(Ac)3-α-D]-OH|116783-35-8|Adamas life|≥98%（以实测数值为准）|B
- 2024-08-20 01:55抑制剂Fmoc-Trp(Me)-OH|Fmoc-Trp(Me)-OH|1334509-86-2|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:55抑制剂Fmoc-Trp(Me)-OH|Fmoc-Trp(Me)-OH|1334509-86-2|Adamas life|≥98%（以实测数值为准）|BR|1g
- 2024-08-20 01:55抑制剂Fmoc-Trp(Me)-OH|Fmoc-Trp(Me)-OH|1334509-86-2|Adamas life|≥98%（以实测数值为准）|BR|250mg
- 2024-08-20 01:55抑制剂FM19G11|FM19G11|329932-55-0|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:55抑制剂Fmoc-Thr[GalNAc(Ac)3-α-D]-OH|Fmoc-Thr[GalNAc(Ac)3-α-D]-OH|116783-35-8|Adamas life|≥98%（以实测数值为准）|B
- 2024-08-20 01:55抑制剂Fmoc-Thr[GalNAc(Ac)3-α-D]-OH|Fmoc-Thr[GalNAc(Ac)3-α-D]-OH|116783-35-8|Adamas life|≥98%（以实测数值为准）|B
- 2024-08-20 01:55抑制剂FLT3-IN-10|FLT3-IN-10|2088735-51-5|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:55抑制剂FM19G11|FM19G11|329932-55-0|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:55抑制剂FM19G11|FM19G11|329932-55-0|Adamas life|≥98%（以实测数值为准）|BR|25mg
